Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hollmann

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
JCI Insight|August 9, 2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumorMichael V Ortiz, Saima Ahmed, Melissa Burns, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Nature Methods|October 8, 2025
Automated classification of cellular expression in multiplexed imaging data with NimbusJosef Lorenz Rumberger, Noah F Greenwald, Jolene S Ranek, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entityNatasha Lewis, Robert A Soslow, Deborah F Delair, et al.
Nature|March 25, 2011
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onsetCraig J Ceol, Yariv Houvras, Judit Jane-Valbuena, et al.
Nature Cancer|August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancerRami S Vanguri, Jia Luo, Andrew T Aukerman, et al.
Nature Communications|April 20, 2022
Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenograftsRebecca Caeser, Jacklynn V Egger, Shweta Chavan, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
JCI Insight|August 9, 2019
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumorMichael V Ortiz, Saima Ahmed, Melissa Burns, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Nature Methods|October 8, 2025
Automated classification of cellular expression in multiplexed imaging data with NimbusJosef Lorenz Rumberger, Noah F Greenwald, Jolene S Ranek, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entityNatasha Lewis, Robert A Soslow, Deborah F Delair, et al.
Nature|March 25, 2011
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onsetCraig J Ceol, Yariv Houvras, Judit Jane-Valbuena, et al.
Nature Cancer|August 29, 2022
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancerRami S Vanguri, Jia Luo, Andrew T Aukerman, et al.
Nature Communications|April 20, 2022
Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenograftsRebecca Caeser, Jacklynn V Egger, Shweta Chavan, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.
Pageof 10